Latest news with #MultipleMyeloma
Hindustan Times
10 hours ago
- Health
- Hindustan Times
India's active Covid-19 cases rise to 6,133, six deaths in last 24 hours
India's active Covid-19 case tally has crossed the 6,000-mark with 378 fresh cases reported in the last 24 hours, Ministry of Health and Family Welfare's (MoHFW) data on Sunday, June 8, showed. India's active Covid-19 case tally stood at 6,133, with Kerala making the biggest contribution in the fresh infections, followed by Gujarat and West Bengal. -Active Covid-19 cases in India: India's active Covid-19 cases rose by 378 since Saturday to stand at 6,133, while 753 people with the infection were cured or discharged in the last 24 hours, the health ministry's data on Sunday showed. -Covid deaths: India also logged six deaths between Saturday and Sunday – two in Karnataka, three in Kerala and one in Tamil Nadu. Details of which are as follows: Karnataka - A 4- year old male with Cor pulmonale, Pulmonary Arterial Hypertension and incidental Covid-19 positive, a 78-year old male with Ischemic Heart Disease, Immune Thrombocytopenic Purpura (and incidental Covid positive. -Kerala Covid deaths: Among the three Covid fatalities in Kerala was a 51-year-old male with SHT, CAD, CKD, a 64-year-old ma;e with T2 DM, CKD, oesophageal adenocarcinoma with metastasis and a 92-year-old male with CAD-Post CABG, CKD Multiple Myeloma, AKI, as per the health ministry. In Tamil Nadu, the patient was a 42-year old male with uncontrolled Diabetes Mellitus, Acute Kidney Disease and seizure disorder. -Kerala, Gujarat log highest cases: Kerala, Gujarat, West Bengal, Rajasthan and Delhi recorded most cases in the last 24 hours. Kerala recorded 144 fresh Covid cases, Gujarat 105, West Bengal 71, Gujarat 24 and Delhi 21. Of the total 6,133 active Covid-19 cases in India, Kerala has the highest share with 1,950 infections. -Cured/discharged: Meanwhile, the number of Covid patients cured or discharged since January 1 this year stood at 6,237 on Sunday. Since January this year, 65 deaths have been reported in the country. There were a total of 257 active patients in the country on May 22.
Yahoo
2 days ago
- Business
- Yahoo
Heidelberg Pharma to Present at the Life Sciences Virtual Investor Forum June 12th
Heidelberg Pharma invites individual and institutional investors, as well as advisors and analysts, to attend online at LADENBURG, Germany, June 06, 2025 (GLOBE NEWSWIRE) -- Heidelberg Pharma AG (XETRA: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that Andreas Pahl, CEO of Heidelberg Pharma, will present live at the Life Sciences Virtual Investor Forum hosted by on June 12th, 2025. Heidelberg Pharma's lead candidate, HDP-101, a BCMA-targeting ADC with the novel payload Amanitin, is being evaluated in a Phase I/IIa clinical trial for the treatment of relapsed or refractory Multiple Myeloma. HDP-101 is showing promising results, including a prolonged complete response in a patient who had undergone extensive prior treatment. The patient has received continuous treatment with HDP-101 alone for over 19 months, showing excellent tolerability of the drug. In addition, promising biological activity and objective improvements were observed in several patients, underscoring the potential of HDP-101 as a treatment option for Multiple Myeloma. Dose escalation is continuing, and the study is advancing in cohort 8. Furthermore, the second candidate, HDP-102, a CD-37-targeting ADC with the novel payload Amanitin, has recently entered clinical development and the first patient has been dosed in a Phase I study for the treatment of non-Hodgkin lymphoma (NHL). DATE: June 12th TIME: 10:00 AM ETLINK: REGISTER HEREAvailable for 1x1 meetings: June 12th and 13th This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates. Learn more about the event at Recent Company Highlights Heidelberg Pharma Announced First Patient Dosed in Phase I Study of Amanitin-based ADC Candidate HDP-102 for Non-Hodgkin Lymphoma Heidelberg Pharma to Present Promising New Clinical Data on its Lead ATAC Candidate HDP-101 at EHA 2025 PR: Heidelberg Pharma Amended Royalty Financing with HealthCare Royalty About Heidelberg Pharma Heidelberg Pharma is a biopharmaceutical company working on a new treatment approach in oncology and developing novel drugs based on its ADC technologies for the targeted and highly effective treatment of cancer. ADCs are antibody-drug conjugates that combine the specificity of antibodies with the efficacy of toxins to fight cancer. Selected antibodies are loaded with cytotoxic compounds, the so-called payloads, that are transported into diseased cells. Inside the cells, the toxins then unleash their effect and kill the diseased cells. Heidelberg Pharma uses several compounds and has built up an ADC toolbox that overcomes tumor resistance via numerous pathways and addresses different types of cancer using various antibodies. The goal is to develop targeted and highly effective ADCs for the treatment of a variety of malignant hematologic and solid tumors. Heidelberg Pharma is the first company to use the compound Amanitin from the green death cap mushroom in cancer therapy. The biological mechanism of action of the toxin represents a new therapeutic modality and is used as a compound in the Amanitin-based ADC technology, the so-called ATAC technology. The company is based in Ladenburg, Germany, and is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA. More information is available at ATAC® is a registered trademark of Heidelberg Pharma Research GmbH. ITAC™, ETAC™ are pending trademark applications of Heidelberg Pharma Research GmbH. About Virtual Investor Conferences®Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors. Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors. CONTACTS:Heidelberg Pharma AG Sylvia Wimmer Director Corporate CommunicationsTel.: +49 89 41 31 38-29E-mail: investors@ Gregor-Mendel-Str. 22, 68526 Ladenburg Virtual Investor Conferences John M. ViglottiSVP Corporate Services, Investor AccessOTC Markets Group (212) 220-2221johnv@
Yahoo
2 days ago
- Business
- Yahoo
Heidelberg Pharma to Present at the Life Sciences Virtual Investor Forum June 12th
Heidelberg Pharma invites individual and institutional investors, as well as advisors and analysts, to attend online at LADENBURG, Germany, June 06, 2025 (GLOBE NEWSWIRE) -- Heidelberg Pharma AG (XETRA: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that Andreas Pahl, CEO of Heidelberg Pharma, will present live at the Life Sciences Virtual Investor Forum hosted by on June 12th, 2025. Heidelberg Pharma's lead candidate, HDP-101, a BCMA-targeting ADC with the novel payload Amanitin, is being evaluated in a Phase I/IIa clinical trial for the treatment of relapsed or refractory Multiple Myeloma. HDP-101 is showing promising results, including a prolonged complete response in a patient who had undergone extensive prior treatment. The patient has received continuous treatment with HDP-101 alone for over 19 months, showing excellent tolerability of the drug. In addition, promising biological activity and objective improvements were observed in several patients, underscoring the potential of HDP-101 as a treatment option for Multiple Myeloma. Dose escalation is continuing, and the study is advancing in cohort 8. Furthermore, the second candidate, HDP-102, a CD-37-targeting ADC with the novel payload Amanitin, has recently entered clinical development and the first patient has been dosed in a Phase I study for the treatment of non-Hodgkin lymphoma (NHL). DATE: June 12th TIME: 10:00 AM ETLINK: REGISTER HEREAvailable for 1x1 meetings: June 12th and 13th This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates. Learn more about the event at Recent Company Highlights Heidelberg Pharma Announced First Patient Dosed in Phase I Study of Amanitin-based ADC Candidate HDP-102 for Non-Hodgkin Lymphoma Heidelberg Pharma to Present Promising New Clinical Data on its Lead ATAC Candidate HDP-101 at EHA 2025 PR: Heidelberg Pharma Amended Royalty Financing with HealthCare Royalty About Heidelberg Pharma Heidelberg Pharma is a biopharmaceutical company working on a new treatment approach in oncology and developing novel drugs based on its ADC technologies for the targeted and highly effective treatment of cancer. ADCs are antibody-drug conjugates that combine the specificity of antibodies with the efficacy of toxins to fight cancer. Selected antibodies are loaded with cytotoxic compounds, the so-called payloads, that are transported into diseased cells. Inside the cells, the toxins then unleash their effect and kill the diseased cells. Heidelberg Pharma uses several compounds and has built up an ADC toolbox that overcomes tumor resistance via numerous pathways and addresses different types of cancer using various antibodies. The goal is to develop targeted and highly effective ADCs for the treatment of a variety of malignant hematologic and solid tumors. Heidelberg Pharma is the first company to use the compound Amanitin from the green death cap mushroom in cancer therapy. The biological mechanism of action of the toxin represents a new therapeutic modality and is used as a compound in the Amanitin-based ADC technology, the so-called ATAC technology. The company is based in Ladenburg, Germany, and is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA. More information is available at ATAC® is a registered trademark of Heidelberg Pharma Research GmbH. ITAC™, ETAC™ are pending trademark applications of Heidelberg Pharma Research GmbH. About Virtual Investor Conferences®Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors. Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors. CONTACTS:Heidelberg Pharma AG Sylvia Wimmer Director Corporate CommunicationsTel.: +49 89 41 31 38-29E-mail: investors@ Gregor-Mendel-Str. 22, 68526 Ladenburg Virtual Investor Conferences John M. ViglottiSVP Corporate Services, Investor AccessOTC Markets Group (212) 220-2221johnv@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Fashion Value Chain
2 days ago
- Health
- Fashion Value Chain
Fortis Vashi Launches Specialised Blood Disorder Clinic
Fortis Hiranandani Hospital, Vashi, today launched the Blood Disorder Clinic in Navi Mumbai-a pioneering center dedicated to the diagnosis, treatment, and management of blood-related conditions. The unit, helmed by Dr Subhaprakash Sanyal, Director-Fortis Institute of Blood Disorders, Fortis Hospitals Mumbai, was inaugurated by Dr S Narayani, Business Head-Maharashtra, Fortis Hospitals and Mr Nitin Kamaria, Facility Director, Fortis Hiranandani Hospital Vashi. (L-R) Mr Nitin Kamaria, Dr Subhaprakash Sanyal, Dir. Institute of Blood Disorders, and Dr S. Narayani at the inauguration of Blood Disorder Clinic The Blood Disorder Clinic, a subset of Fortis Institute of Blood Disorders, will offer specialized care for life-threatening blood cancers such as Multiple Myeloma, Leukemia, and other serious hematologic conditions, as well as non-cancerous blood disorders like Anemia and Hematomas. Additionally, the clinic will provide cutting-edge CAR T-cell Therapy, a ground-breaking treatment offering new hope for patients with certain types of Blood Cancers. It aims to provide comprehensive, patient-centered services for individuals in need of expert care. Dr Subhaprakash Sanyal, Director-Fortis Institute of Blood Disorders, will be work closely with Dr Hamza Dalal, Consultant-Haematology and a team of specialists, to lead the Blood Disorder Clinic, providing dedicated care and support for patients and their caregivers. 'This Blood Disorder Clinic reflects our commitment to providing specialized care for those with blood-related conditions. We understand the challenges these patients face, and our goal is to provide them with the most advanced treatments, ongoing support, and a compassionate environment that promotes healing and holistic well-being. A first-of-its-kind program in Navi Mumbai is designed to be a safe space for patients to heal,' said Dr S. Narayani, Business Head-Maharashtra, Fortis Hospitals. 'This clinic represents a rare and invaluable resource in an area of treatment that is often overlooked and under-practiced. For those battling complex blood disorders and life-threatening conditions like Leukemia or Multiple Myeloma, having access to specialized care is not just a necessity-its a lifeline. The Blood Disorder Clinic will offer expert treatment in a field that requires precision, dedication, and a deep understanding of these rare and challenging conditions,' said Dr Subhaprakash Sanyal, Director-Fortis Institute of Blood Disorders, Fortis Hospitals Mumbai. With the launch of the Blood Disorder Clinic, Fortis Hiranandani Hospital, Vashi is redefining specialized care for blood-related conditions in Navi Mumbai. More than just a medical facility, the clinic is a lifeline for patients and their families-providing expert guidance, innovative therapies, and unwavering support every step of the way. As it embarks on this journey, the clinic is committed to setting new standards in blood disorder care, ensuring that every patient receives not just world-class treatment, but also the compassion and dignity they deserve. About Fortis Healthcare Limited Fortis Healthcare Limited – an IHH Healthcare Berhad Company – is a leading integrated healthcare services provider in India. It is one of the largest healthcare organizations in the country with 27 healthcare facilities, ~4,750 operational beds (including O&M facilities), and over 400 diagnostics centers (including JVs). The Company is listed on the BSE Ltd and National Stock Exchange (NSE) of India. It draws strength from its partnership with a global major and parent company – IHH, to build upon its culture of world-class patient care and superlative clinical excellence. Fortis employs over 23,000 people (including Agilus Diagnostics Limited) who share its vision of becoming the world's most trusted healthcare network. Fortis offers a full spectrum of integrated healthcare services ranging from clinics to quaternary care facilities and a wide range of ancillary services.
Indian Express
15-05-2025
- Health
- Indian Express
‘I went into premature chemo-induced menopause at 37', reveals Lisa Ray; we ask a gynaecologist to explain the condition
For many, menopause is a midlife transition. But for actor and cancer survivor Lisa Ray—and thousands of women undergoing chemotherapy—it arrives far earlier, with little warning and even less conversation. Ray recently shared her story on Instagram, and her honesty struck a chord. 'This is me in menopause,' she wrote. 'Menopause does not have one face… I went into premature chemo-induced menopause at 37.' 'At that time, it was the least of my worries. I had a blood cancer called Multiple Myeloma to contend with… But after recovering, I could focus on what being in menopause suddenly at 37 would mean. And I had no one to talk to,' Lisa added. At 53, she's now choosing to speak up—not just for herself but for everyone navigating this unspoken terrain. A post shared by Lisa Ray (@lisaraniray) 'Chemotherapy-induced menopause is a significant and life-altering consequence for many women,' explains Dr Chetna Jain, Director of the Department of Obstetrics and Gynaecology at Cloudnine Group of Hospitals, Gurgaon. Chemotherapy doesn't just target cancer cells; it also harms healthy, fast-dividing cells—including those in the ovaries. The result? The ovaries stop producing hormones like estrogen and progesterone, pushing the body into sudden menopause. This condition is also known as iatrogenic menopause or chemotherapy-induced ovarian failure. For some, the change is temporary. For others—especially women over 40—it can be permanent. Women under 30 are more likely to see their periods return after treatment, but each case varies. Chemo-induced menopause can hit hard. Hot flashes, night sweats, mood swings, fatigue, vaginal dryness, and loss of libido are common. Beyond the symptoms, the emotional impact can be just as intense—especially for younger women who weren't expecting to face menopause for decades. 'Both menopause and disease-induced menopause have been treated with shame and silence for too long,' Lisa wrote. It's that silence that she's now breaking. Dr Jain stresses the importance of early diagnosis and personalised care. 'Gynecologists play a key role in offering support, symptom relief, and fertility guidance,' she says. Here's how many women manage this sudden shift: The shift into menopause—especially early—isn't just physical. It affects self-image, relationships, and mental health. But the more we talk, the more women can find comfort, clarity, and strength. As Lisa puts it, 'Maybe that's why I am talking now at 53 and embracing the authenticity that comes at this age.' DISCLAIMER: This article is based on information from the public domain and/or the experts we spoke to. Always consult your health practitioner before starting any routine.
